Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of chemoimmunotherapy versus venetoclax-based combinations in fit, previously untreated chronic lymphocytic leukemia
2015-004936-36Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax, obinutuzumab, ibrutinib, rituximab, fludarabine and 2 more in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by University of Cologne. Primary endpoints: Minimal residual disease negativity in peripheral blood at month 15 and Progression-free survival. Started Sep 2016; status: completed.
02
Drugs
venetoclaxobinutuzumabibrutinibrituximabfludarabine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-004936-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004936-36.